



Figure 1. Detailed sequence diversity of the SARS-CoV-2 isolates from the 2 patient samples (date of sample collection is indicated as DD-MM-YY). On top the representation of the SARS-CoV-2 genome (genes are indicated) and below the nucleotide substitutions (in green shared and in red distinct substitutions between the 2 isolates) in relation to SARS-CoV-2 reference genome (NC_045512.2).

and resumed work. Forty-eight days after primary infection, she again developed COVID-19-like symptoms similar to those experienced previously. Exposure history disclosed a recent close contact for >15 minutes while wearing a surgical mask during care of a COPD patient with respiratory symptoms not wearing a mask during physical examination and who was diagnosed with COVID-19. A SARS-CoV-2 RT-PCR on a naso-oro-pharyngeal specimen was positive on November 12. No laboratory abnormalities, including immunocompromising conditions, were found. Antibody testing after the first COVID-19 episode was not performed but anti-SARS-CoV-2 IgG antibodies were detected by a chemiluminescent microparticle assay (Abbott Diagnostics, Chicago, IL) 11 days into the second disease episode.

Results

Swab samples from the 2 disease episodes were available. Multiplex RT-PCR Ct values of the 3 target gene sequences (ORF1ab, N, and E) from each disease episode specimens were 31/33/25 and 30.5/29.8/31.2, respectively. Viral whole genome-sequencing (with the Ion AmpliSeq™ SARS-CoV-2 Research Panel; Thermo Fisher Scientific, Waltham, MA), phylogenetic analysis and lineage/clade affiliation was performed as previously described.¹⁰ The sequencing of the viral genome of the paired samples (Fig. 1) revealed 2 different variants affiliated in 2 different clades: 20B in the first infection and 20A in the second. The 2 variants shared 4 nucleotide substitutions in relation to SARS-CoV-2 reference genome (NC_045512.2), but diverged by 20 nucleotide substitutions located throughout the SARS-CoV-2 genome. This rate of divergence exceeds largely the low rate of mutation described for SARS-CoV-2, and the fact that the viral specimens were affiliated in 2 distinct clades further supports the occurrence of reinfection.

Discussion

Viruses, such as SARS-CoV-2, that infect mucosal surfaces and do not have a viraemic phase, result in transient antibody responses that are detected for months or a few years.¹¹ Despite studies of neutralizing antibody responses against SARS-CoV-2 spike protein showing a decline in titres over time (being detectable in some studies for at least 5 months after primary infection), the long-term duration of antibody responses is not yet fully known.¹² On one hand, failure to detect antibodies in serum in an individual after natural infection or even vaccination does not mean that they will not rapidly produce antibody upon re-exposure to the same pathogen, which is attributed to memory B cells and long-lived plasma cells, with a more rapid and stronger

response and thus mitigating disease severity or preventing reinfection altogether.¹² On the other hand, the presence of neutralizing antibodies during primary infection may be insufficient to confer protection against reinfection, as recently illustrated by a case of a solid organ transplant recipient with COVID-19, whose underlying immune deficiencies (ie, low naïve T CD4+ pools) resulted in a poor neutralizing antibody quality insufficient to protect against SARS-CoV-2 reinfection.² To date it is not yet clear if SARS-CoV-2 reinfections are isolated events in individuals unable to mount an effective adaptive immune response, and ultimately what is required to develop strong humoral responses, or if they will be seen more frequently in the setting of newly emerging variants with the potential to evade immune response. Importantly, regarding this last point, in the SARS-CoV-2 Immunity and Reinfection Evaluation study, the variant of concern B.1.1.7 (renamed as Alpha variant) circulated during the observation period, causing nearly 50% of all infections, although not seeming to have an influence on the rates of reinfection.⁶

When it comes to shaping the future dynamics of SARS-CoV-2 circulation, a key aspect of reinfections pertains their infectiousness. Possible infectiousness means herd immunity from infection or vaccination is unlikely to be sufficient to eliminate the virus if reinfection cases are seen more frequently. As such, current focus should be placed not only in comparing immunity following natural infection and that elicited by vaccination to better define vaccine schedules, but also on ensuring personal protective measures in the highly exposed healthcare setting are not overlooked even after acquired immunity, by natural infection, vaccination or both, at least until more is known about the type and duration of protection they confer.

Acknowledgements

The authors would like to thank the healthcare professional for her willingness to collaborate, critical approach and the accuracy with which she provided us with her data, and also for consent.

Conflicts of interest

The authors have no conflicts of interest to disclose.

This case report was presented at the 9º Congresso Pandemias na Era da Globalização” in May 2021.

References

- [1] To KK, Hung IF, Ip JD, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole

- genome sequencing. *Clin Infect Dis*. 2020;ciaa1275. doi: 10.1093/cid/ciaa1275.
- [2] Klein J, Brito A, Trubin P, et al. Longitudinal immune profiling of a SARS-CoV-2 reinfection in a solid organ transplant recipient. *Res Sq* [Preprint]. 2021;rs.3.rs-405958. doi: 10.21203/rs.3.rs-405958/v1.
 - [3] Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371:eabf4063.
 - [4] Grandjean L, Saso A, Ortiz AT, et al. Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. *Clin Infect Dis*. 2021;ciab607. doi: 10.1093/cid/ciab607.
 - [5] Abu-Raddad LJ, Chemaitelly H, Coyle P, et al. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy. *EClinicalMedicine*. 2021;35:100861.
 - [6] Hall VJ, Foulkes S, Charlett A, et al. SIREN Study Group SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet*. 2021;397:1459–1469.
 - [7] Krammer F. Correlates of protection from SARS-CoV-2 infection. *Lancet*. 2021;397:1421–1423.
 - [8] Babiker A, Marvil CE, Waggoner JJ, Collins MH, Piantadosi A. The importance and challenges of identifying SARS-CoV-2 reinfections. *J Clin Microbiol*. 2021;59:e02769–e2820.
 - [9] Center for Disease Control and Prevention. Investigative criteria for suspected cases of SARS-CoV-2 reinfection (ICR). CDC; 2020. Available at: <https://www.cdc.gov/coronavirus/2019-ncov/php/invest-criteria.html> (accessed on April 18, 2021).
 - [10] Pedro N, Silva CN, Magalhães AC, et al. Dynamics of a dual SARS-CoV-2 lineage co-infection on a prolonged viral shedding COVID-19 case: insights into clinical severity and disease duration. *Microorganisms*. 2021;9:300.
 - [11] Cohen JI, Burbelo PD. Reinfection with SARS-CoV-2: implications for vaccines. *Clin Infect Dis*. 2020;ciaa1866. doi: 10.1093/cid/ciaa1866.
 - [12] Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020;370:1227–1230.